drugset
drugset / Trial / NCT04124003

A Study to Assess the Drug-drug Interaction of BMS-963272 and Rosuvastatin

NCT04124003 ↗

Phase 1 Completed 28 enrolled Bristol-Myers Squibb
NaSingle-groupOpen-labelDiagnostic

Summary

Phase 1 study that assesses the effect of BMS-963272 on exposure of rosuvastatin in healthy participants

Timeline

Start
2019-10-08
Primary completion
2020-01-03
Completion
2020-01-03

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-963272 Small molecule — —
Subject Rosuvastatin Small molecule — —

Indications

No indication recorded.